Compare OTEX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTEX | LGND |
|---|---|---|
| Founded | 1991 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.0B |
| IPO Year | 1998 | 1997 |
| Metric | OTEX | LGND |
|---|---|---|
| Price | $24.88 | $314.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | $28.14 | ★ $361.27 |
| AVG Volume (30 Days) | ★ 1.4M | 183.8K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.49% | N/A |
| EPS Growth | 56.36 | ★ 2886.36 |
| EPS | ★ 0.64 | 0.31 |
| Revenue | ★ $2,815,241,000.00 | $141,102,000.00 |
| Revenue This Year | N/A | $8.82 |
| Revenue Next Year | $1.67 | $31.67 |
| P/E Ratio | ★ $38.98 | $1,028.35 |
| Revenue Growth | 22.88 | ★ 29.48 |
| 52 Week Low | $19.78 | $175.89 |
| 52 Week High | $34.17 | $326.63 |
| Indicator | OTEX | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 54.39 |
| Support Level | $21.70 | $277.97 |
| Resistance Level | $25.57 | $319.83 |
| Average True Range (ATR) | 0.70 | 11.02 |
| MACD | -0.34 | -0.13 |
| Stochastic Oscillator | 20.71 | 60.62 |
Open Text Corp provides data management for enterprise AI, offering a secure data foundation and trusted context for credible AI outcomes across private, public, and sovereign cloud, managed cloud services, API, and on-premises environments. The Company also provides cybersecurity solutions to protect sensitive data, applications and systems across complex hybrid environments, including identity and access management, threat detection and response, data protection and application security. It serves private, public, and regulated sectors, including retail, financial services, government, manufacturing, healthcare, energy, and logistics, with clients. Geographically, it derives maximum revenue from the Americas.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.